Regulatory and Safety Aspects of Cell and Gene Therapy

Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.


  • guidelines of cell therapy
  • safety precautions

Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy

July 19-20, 2021

25th Global Congress on Biotechnology

Vienna, Austria
August 06-07, 2021

International Conference on Plant Genomics

London, UK
August 13-14, 2021

36th International Conference on Immunology & Immunogenetics

Edinburgh, Scotland
September 13-14, 2021

4th Annual Summit on Cell and Gene Therapy

Prague, Czech Republic
September 22-23, 2021

13th World Congress on Cell and Stem Cell Research

Madrid, Spain
September 27-28, 2021

15th International Conference on Genomics & Pharmacogenomics

Vancouver, Canada
October 18-19, 2021

20th International Conference on Structural Biology

Rome, Italy
November 20-21, 2021

26th World Congress on Industrial Biotechnology

Chicago, USA
December 07-08, 2021

2nd World Congress on Cell and Structural Biology

Sydney, Australia
December 09-10, 2021

2nd International Conference on Geriatrics and Ageing

Sydney, Australia

Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in